Abstract
Terminal ileal biopsies were prospectively obtained and stained specifically for mast cells in 20 patients with irritable bowel syndrome (IBS) and 15 controls. The number of terminal ileal mast cells per high powered field (MC/HPF) (mean ±SEM) was 23.3±3.1 for, IBS and 6.8±1.1 for controls (P=0.0001). The diarrhea IBS subgroup had the greatest number of MC/HPF. No correlation was found between terminal ileal mucosal mast cell counts (MMCC) and the number of Manning criteria present or the functional bowel disease score (r=0.06 andr=−0.31, respectively). We conclude that terminal ileal MMCC are significantly elevated in a majority of patients with IBS. The mast cell may be responsible for the altered visceral perception found in the gastrointestinal tract in patients with IBS. The poor correlation of the MMCC to the clinical features of IBS may be the result of the dynamic state of the mast cell.
Similar content being viewed by others
References
Thompson WG, Heaton KW: Functional bowel disorders in apparently healthy people. Gastroenterology 79:283–288, 1980
Kirsner JB, Palmer WL: The irritable colon. Gastroenterology 34:491–501, 1958
Prior A, Maxton DG, Whorwell PJ: Anorectal manometry in irritable bowel syndrome: differences between diarrhea and constipation predominant subjects. Gut 31:458–462, 1990
Ritchie J: Pain from distension of the pelvic colon by inflating a balloon in the irritable bowel syndrome. Gut 14:125–132, 1973
Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, Shabsin HS, Schuster MM: Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 98:1187–1192, 1990
Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR: Dysmotility of the small intestine in irritable bowel syndrome. Gut 29:1236–1243, 1988
Stead RH, Dixon MF, Bramwell NH, Riddell RH, Bienenstock J: Mast cells are closely opposed to nerves in the human gastrointestinal mucosa. Gastroenterology 97:575–585, 1989
Perdue MH, Masson S, Wershil BK, Galli SJ: Role of mast cells in ion transport abnormalities associated with intestinal anaphylaxis. Correction of the diminshed secretory response in genetically mast cell-deficient W/Wv mice by bone marrow transplantation. J Clin Invest 87:687–693, 1991
Befus D: Regulation of gastrointestinal mast cells. Dig Dis Sci 37(6):967 (A-5), 1992
Oddson E, Rask-Madsen J, Krag E: A secretory epithelium of the small intestine with measured sensitivity to bile acids in irritable bowel syndrome associated with diarrhea. Scand J Gastroenterol 13:409–416, 1978
Kellow JE, Phillips SF: Altered small bowel motility in irritable bowel syndrome is correlated, with symptoms. Gastroenterology 92:1885–1893, 1987
Phillips S, Camilleri M: The ileocecal area and the irritable bowel syndrome. Gastroenterol Clin North Am 20(2):297–311, 1991
Trotman IF, Price CC: Bloated irritable bowel syndrome defined by dynamic99mTc-bran scan. Lancet 2:364–366, 1989
Manning AP, Thompson WG, Heaton KW, Morris AF: Towards positive diagnosis of the irritable bowel. Br Med J 2:653–654, 1978
Talley NJ, Phillips SF, Melton LJ, Wiltgen C, Zinsmeister AR: A patient questionnaire to identify bowel disease. Ann Intern Med 111:671–674, 1989
Talley NJ, Phillips SF, Melton LJ, Mulvihill C, Wiltgen C Zinsmeister AR: Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 31:77–81, 1990
Matter SE, Bhatia PS, Miner PB; Evaluation of antral mast cells in nonulcer dyspepsia. Dig Dis Sci 35:1358–1363, 1990
Lindeman RH, Merenda PF, Gold RZ: Introduction to Bivariate and Multivariate Analysis. Dallas, Scott, Foresman and Company, 1980
Chaudhary NA, Truelove SC: The irritable colon syndrome. Q J Med 123:307–322, 1962
Hiatt RB, Katz L: Mast cells in inflammatory conditions of the gastrointestinal tract. Am J Gastroenterol 37:541–545, 1962
Konturek SJ, Siebers R. Role of histamine H1- and H2- receptors in myoelectric activity of small bowel in the dog. Am J Physiol 238:G50-G56, 1980
Cooke HJ, Wang YZ, Rogers R: Mechanisms of neuralimmune system interactions. Dig Dis Sci 37(6):966(A-4), 1992
Cooke HJ, Nemeth PR, Wood JD: Histamine action on guinea pig ileal mucosa. Am J Physiol 246:G372-G377, 1984
Theoharides TC, Sant GR: Bladder mast cell activation in interstitial cystitis. Semin Urol 9(2):74–87, 1991
Askenase PW: Immunopathology of parasitic diseases: involvement of basophils and mast cells. Springer Semin Immunopathol 2:417–442, 1980
Befus AD, Bienenstock J: Immunologically mediated intestinal mastocytosis inNippostrongylus brasiliensis-infected rats. Immunology 38:95–101, 1979
Stefanini GF, Prati E, Albini MC, Piccinini G, Capelli S, Castelli E, Mazzetti M, Gasbarrini G: Oral disodium cromoglycate treatment on irritable bowel syndrome. An open study on 101 subjects with diarrheic type. Am J Gastroenterol 87:55–57, 1992
Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW, Greenbaum RB, Matson RW, Stein GE, Dean HA, Halvorsen NA, Rosen LW: Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 32:257–266, 1987
Hislop IG: Psychological significance of the irritable colon syndrome. Gut 12:452–457, 1971
Diamond S: Amitriptyline in the treatment of gastrointestinal disorders. Psychosomatics 5:221–224, 1964
Kasich AM: Management of emotional disorders, anxiety and depression, in patients with gastrointestinal disease. Curr Ther Res 7(9):542–547, 1965
Thompson WG: A strategy for management of the irritable bowel. Am J Gastroenterol 81(2):95–100, 1986
Brannan DP, Drossman DA: Toward a newer understanding of irritable bowel syndrome. Contemp Intern Med September: 73–91, 1991
Kachur JF, Allbee WE, Gaginella TS: Antihistaminic and antimuscarinic effects of amitriptyline on guinea pig ileal electrolyte transport and muscle contractilityin vitro. J Pharmacol Exp Ther 245(2):455–459, 1988
Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW: Differential release of serotonin and histamine from mast cells. Nature 297:229–231, 1982
Prior A, Read NW: Reduction of rectal sensitivity and postprandial motility by granisetron, a 5HT3 receptor antagonist, in patients with irritable bowel syndrome (BIS). Gut 31:A1174, 1990
Mathias JR, Ferguson KL, Clench MH: Debilitating “functional” bowel disease controlled by leuprolide acetate, gonadotropin-releasing hormone (GnRH) analog. Dig Dis Sci 34(5):761–766, 1989
Plourde V, Mertz H, Sytnik B, Tache Y, Mayer EA: Effects of somatostatin analogue on sensory perception to rectal balloon distension. Dig Dis Sci 47(6):976(A-14), 1992
Klein KB: Controlled treatment trials in the irritable bowel syndrome: A critique. Gastroenterology 95:232–241, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weston, A.P., Biddle, W.L., Bhatia, P.S. et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Digest Dis Sci 38, 1590–1595 (1993). https://doi.org/10.1007/BF01303164
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01303164